Synergistic Stimulation with Different TLR7 Ligands Modulates Gene Expression Patterns in the Human Plasmacytoid Dendritic Cell Line CAL-1

Tobias Hilbert, Folkert Steinhagen, Christina Weisheit, Georg Baumgarten, Andreas Hoeft, and Sven Klaschik

Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany

Correspondence should be addressed to Sven Klaschik; sven.klaschik@ukb.uni-bonn.de

Received 7 August 2015; Revised 31 October 2015; Accepted 3 November 2015

Academic Editor: Carolina T. Piñeiro

Copyright © 2015 Tobias Hilbert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. TLR7 ligation in plasmacytoid dendritic cells is promising for the treatment of cancer, allergy, and infectious diseases; however, high doses of ligands are required. We hypothesized that the combination of structurally different TLR7 ligands exponentiates the resulting immune response.

Methods. CAL-1 (human pDC line) cells were incubated with the TLR7-specific adenine analog CL264 and single-stranded 9.2s RNA. Protein secretion was measured by ELISA. Microarray technique was used to detect modified gene expression patterns upon synergistic stimulation, revealing underlying functional groups and networks. Cell surface binding properties were studied using FACSanalysis. Results. CL264 in combination with 9.2s RNA significantly enhanced cytokine and interferon secretion to supra-additive levels. This effect was due to a stronger stimulation of already regulated genes (by monostimulation) as well as to recruitment of thus far unregulated genes. Top scoring canonical pathways referred to immune-related processes. Network analysis revealed IL-1β, IL-6, TNF, and IFN-β as major regulatory nodes, while several minor regulatory nodes were also identified. Binding of CL264 to the cell surface was enhanced by 9.2s RNA. Conclusion. Structurally different TLR7 ligands act synergistically on gene expression patterns and on the resulting inflammatory response. These data could impact future strategies optimizing TLR7-targeted drug design.

1. Introduction

Immune cells utilize toll-like receptors (TLRs) to sense pathogen associated molecular patterns (PAMPs), which represents the starting point of the innate immune response [1]. Plasmacytoid dendritic cells (pDCs) are at the nexus between innate and adaptive immunity and are thereby key contributors to the host’s response to various pathogens. Furthermore, pDCs are the major source of type I interferon (IFN) in humans and are, thus, of particular importance for antiviral immunity and autoimmune diseases [2]. In human beings, pDCs and, to a lesser extent, B cells constitutively express TLR7 and TLR9, both of which sense nucleic acids [3–5]. TLR7, originally known to recognize imidazoquinoline derivatives (e.g., imiquimod and resiquimod/B 848) and guanine analogs (e.g., loxoribine), recognizes single-stranded (ss) RNA derived from RNA viruses such as influenza A virus, vesicular stomatitis virus, and human immunodeficiency virus [1]. In pDCs, TLR7 recognizes these ligands in specialized endolysosomes, resulting in the subsequent activation of NF-κB and interferon regulatory factor (IRF) 7 via MyD88, and induces production of inflammatory cytokines and type I IFN, respectively [1]. Thus, studying TLR7 in human pDCs is of particular interest. Preclinical studies utilizing TLR7 ligation revealed promising results in the treatment of cancer, allergy, and infectious diseases [6, 7]. However, clinical studies using TLR7 ligands systemically are problematic, as they have been associated with severe side effects such as hematological toxicity [6]. Thus, pharmacological strategies are needed to achieve potent TLR7 responses. One approach is the synergistic use of two compounds. In this study, we hypothesized that the simultaneous use of two structurally
and chemically different TLR7 ligands unfolds synergistic effects on human pDCs. To test this hypothesis, we coadministered the adenine analog CL264, a potent and highly specific TLR7 ligand, together with the natural ssRNA 9.2s RNA to the human pDC line CAL-1. Our data may broaden our understanding of TLR7 activation and could impact future strategies optimizing TLR7-targeted drug design.

2. Materials and Methods

2.1. Materials and Reagents. PBS (pH 7.4) and RPMI 1640 were purchased from Life Technologies (CA, USA). The latter was supplemented with 10% heat inactivated fetal bovine serum (FBS Superior, Biochrom AG, Berlin, Germany) and 2 mmol/L Glutamine (Life Technologies). Cell culture flasks and 24- and 96-well flat-bottom plates were obtained from Greiner Bio-One (Frickenhausen, Germany). CL264 (tirldc264e) and FITC-labeled CL264 (tirlf-c264e) were purchased from InvivoGen (CA, USA) and dissolved in sterile, RNAse-free water (Sigma-Aldrich, MO, USA) containing 10% DMSO (Sigma-Aldrich) and further diluted in culture medium. Greiner Bio-One (Frickenhausen, Germany). Cell culture flasks and 24- and 96-well flat-bottom plates were obtained from Greiner Bio-One (Frickenhausen, Germany). CL264 (tirldc264e) and FITC-labeled CL264 (tirlf-c264e) were purchased from InvivoGen (CA, USA) and dissolved in sterile, RNAse-free water (Sigma-Aldrich, MO, USA) containing 10% DMSO (Sigma-Aldrich) and further diluted in culture medium. Cell culture flasks and 24- and 96-well flat-bottom plates were obtained from Greiner Bio-One (Frickenhausen, Germany). CL264 (tlrlc264e) and 24- and 96-well flat-bottom plates were obtained from InvivoGen (CA, USA) and dissolved in sterile, RNAse-free water [8].

2.2. Culture and Activation of CAL-1 Cells. The human pDC line CAL-1 (kindly provided by Drs. Maeda and Kamihira) was grown in complete medium (RPMI 1640) supplemented with 2 mmol/L Glutamine and 10% heat inactivated FBS and cultured as previously described [9].

For gene expression studies, cells were plated in a 24-well plate (3 × 10⁶ cells in 3 mL per well), and, for ELISA studies, cells were plated in a 96-well plate (2 × 10⁶ cells in 0.2 mL per well). After overnight resting in serum reduced (1% FBS) medium, CAL-1 cells were stimulated with the TLR7 ligand CL264 (5 μg/mL), with 9.2s RNA (2 μg/mL), or with the combination of both. The reagents were diluted in culture medium and added to the cell suspension in the wells of the 96- or 24-well plates, respectively. Vehicle and nonstimulatory Poly-A RNA (2 μg/mL) were used as control. Before stimulation, ORNs were complexed with the polycationic polypeptide poly-L-arginine hydrochloride (PLarg, 2 mg/mL) to facilitate RNA delivery. ORNs were incubated with PLarg for 2 minutes at room temperature before adjusting to the desired concentration by adding culture medium and incubating for another 15 minutes [8]. PLarg alone or 9.2s RNAs not complexed to PLarg were used in control conditions, respectively. After addition of the ligands, the cell density was adjusted to 1 × 10⁶ cells/mL by adding fresh, prewarmed cell culture medium.

After incubating for the indicated periods of time, the supernatant from the 96-well plates was collected and stored at −80°C for later analysis of proinflammatory cytokines and type 1 interferon. From 24-well plates, the cell suspension was carefully aspirated and transferred to a 15 mL conical tube. Cells were sedimented by centrifugation at 2,000 rpm for 5 minutes. The supernatant was discarded and the cell pellet was resuspended in 2 mL TRIzol reagent and stored at −80°C for subsequent extraction of total RNA.

For some secretion experiments, ligands were added sequentially instead of simultaneously with an intermediary wash step. After incubation with a first ligand for 2hrs, the plate was centrifuged, followed by careful aspiration of the medium. Cells were washed 3 times with prewarmed PBS, each with an intermediary centrifugation step. Subsequently, the other ligand was added in prewarmed cell culture medium, and cells were incubated for additional 6 hrs.

2.3. Measurement of Cytokines and IFN-β in Cell Culture Supernatant. TNF-α, IL-6, and IFN-β levels in the cell culture supernatant were quantified using commercially available ELISA kits (BD Biosciences (CA, USA) and PBL Assay Science (NJ, USA), resp.) according to manufacturer instructions.

2.4. Isolation of Total RNA. After thawing cells suspended in TRIzol reagent, they were left at room temperature for another 5 minutes and well pipetted up and down to lyse the cell membrane. 400 μL chloroform was added and the suspension was shaken vigorously, followed by incubation at room temperature for 3 minutes. After centrifugation for 15 minutes at 12,000 rpm and +4°C, the upper aqueous phase was carefully aspirated and transferred into an RNAse-free tube. The RNA was precipitated using 1 mL isopropanol and incubating at room temperature for 10 minutes. After another centrifugation step, the pellet was washed using 75% ethanol. The air-dried RNA pellet was resuspended in RNAse-free water, and the concentration was determined spectrophotometrically (NanoDrop, Thermo Scientific, Germany).

2.5. Microarray Hybridization. Total RNA was incubated with anchored oligo-dT primers at +70°C and subsequently chilled on ice. CDNA synthesis was performed using a mastermix containing first-strand buffer, 20x aminomethyl-dNTP labeling mix, dithiothreitol (DTT), RNAse inhibitor, and reverse transcriptase enzyme (Promega, Germany). Following incubation, residual RNA was degraded by NaOH and HCl incubation. Resulting cDNA was purified using the Qiagen MinElute kit (Qiagen, Germany) and was coupled to Cy3 and Cy5 dyes, respectively, by incubation for 90 min. Cy3-labeled reference and Cy5-labeled sample cDNAs (10 μL...
each) were combined, denatured by heating for 2 minutes at 98°C, and mixed with 36 µL of hybridization solution at +42°C (Ambion, Austin, TX, USA). Murine microarrays (NimbleGen, Roche, Basel, Switzerland) were overlaid with this solution and hybridized for 18 hours at +42°C using an actively mixing MAUI hybridization system (BioMicro Systems, Salt Lake City, UT, USA). After hybridization, the arrays were washed in 1x SSC/0.05% SDS and 0.1x SSC, centrifuged to remove remaining liquid with unbound cDNA, and air-dried. Intensity values were generated using an array scanner (NimbleGen). Data were uploaded to the mAdb database (Microarray Database, a collaboration of CIT/BIMAS and NCI/CCR at the NIH; URL: http://nciarray.nci.nih.gov/) and formatted via the export function for use with BRB ArrayTools (Biometric Research Branch, NCI, Frederick, MY, USA).

2.6. FACS Binding Assay. CAL-1 cells were seeded in 24-well plates one day prior to the experiment and incubated under standard conditions as described above. Fresh cold medium was added together with FITC (5.5 µM), PLarg-complexed 9.2s RNA (2 µg/mL), or FITC-labeled CL264 (5 µg/mL, equaling 5.5 µM) or a combination, respectively (Figure 4(a)). Noncomplexed RNA and PLarg were used as control conditions for 9.2s RNA. Incubation was carried out at +4°C for 10 minutes. Cells suspension was aspirated and washed three times with cold PBS, fixed with PFA for 15 minutes at +4°C, and washed another two times with PBS and once with FACS buffer. Cells were then resuspended in 250 µL FACS buffer, followed by readout on a BD FACS Canto II flow cytometer. FACS data was acquired using BD FACSDiva (version 6.1.2) and analyzed using FlowJo (version 10.0.5) software.

2.7. Statistics. Data are presented as mean of biological triplicates ± SEM. Each experiment was repeated at least three times. Statistical analysis was performed by two-sided unpaired Student’s t-test using GraphPad PRISM (La Jolla, CA, USA). The alpha level was set at 5%.

For the analysis of microarray experiments, data from three independent experiments and three untreated controls was used for statistical analyses. Expression analyses were performed using BRB ArrayTools. Data were background corrected, flagged values were removed, spots in which both signals were <100 were filtered out, ratios were log base 2-transformed, and lowest intensity-dependent normalization was used to adjust for differences in labeling intensities of Cy3 and Cy5 dyes [10]. Analysis was restricted to genes present on >50% of the arrays after filtering. The gene expression profile of all treatment groups was compared to that of the control group. A p value cutoff of 0.001 was used to identify genes whose expression was significantly upregulated after TLR7 ligand stimulation when compared to controls. Data were evaluated using Ingenuity Pathway Analysis (IPA, Ingenuity Systems Inc., Redwood City, CA, USA). IPA maps each gene within a global molecular network, pathways, and functional groups developed from information contained in the Ingenuity Pathways Knowledge Base (see URL: https://analysis.ingenuity.com/pa/info/help/Ingenuity_Network_Algorithm_Whitepaper_FINAL(2)).

3. Results

3.1. Stimulation of CAL-1 Cells with Different TLR7 Ligands: Synergistic Secretion of Proinflammatory Cytokines and Type I Interferon. CAL-1 cells were stimulated with the specific TLR7 ligand CL264 (adenine analog) and the TLR7/8 ligand 9.2s RNA complexed to PLarg. CAL-1 cells do not express TLR8, so response to 9.2s RNA is limited to TLR7 stimulation [11]. Dose titration experiments determined optimal conditions: using concentrations from 0.5 to 10 µg/mL, stimulation with CL264 resulted in a dose-dependent secretion of TNF-α after 6 hours (Figure 1(a)). In contrast, stimulation with 9.2s RNA did not generate any notable response. For further experiments, a submaximal stimulatory concentration of CL264 was used (5 µg/mL). Using this concentration, stimulation with CL264 for up to 12 hours led to a robust, time-dependent release of TNF-α reaching absolute levels of 1347 pg/mL TNF-α into the supernatant (Figure 1(b)). The kinetics of IL-6 secretion was comparable to that of TNF-α with lower absolute cytokine levels (526 pg/mL) after stimulation for 12 hours (Figure 1(c)). In contrast, upon stimulation solely with 9.2s RNA (2 µg/mL), no notable secretion of proinflammatory cytokines was measured. However, the addition of 9.2s RNA to CL264 considerably increased the secretion of TNF-α and IL-6 compared to the monostimulation only with CL264 (Figures 1(b) and 1(c); p < 0.001).

We previously demonstrated that activation of CAL-1 cells with TLR9 ligands induces detectable amounts of type 1 IFN [12]. Accordingly, we assessed a possible synergism of TLR7 stimulation on IFN-β release under the same experimental conditions using CL264 and 9.2s RNA. Again, co-stimulation with CL264 and 9.2s RNA for 12 hours resulted in a marked and significant increase of IFN-β protein compared to monostimulatory conditions (p < 0.001) (Figure 1(d)).

Of note, the synergistic effect of CL264 and 9.2s RNA on CAL-1 cells could be abolished by stimulating the cells sequentially instead of simultaneously. More specifically, no enhanced cytokine secretion could be detected when CL264 was the first stimulus, followed by washing and then ligation with 9.2s RNA. On the other hand, switching the order of stimulation preserved the supra-additive activation even when cells were washed between the ligation steps (Figure 1(e)).

For control experiments, nonstimulatory Poly-A RNA was used instead of 9.2s RNA and had no enhancing effect. Similarly, the use of PLarg alone or 9.2s RNA not complexed with PLarg prior to stimulation had no additive effect (Figure 1(f)).

3.2. Changes in Gene Expression Patterns of CAL-1 Cells upon Stimulation with CL264 and/or 9.2s RNA. To gain more insights into the present findings, microarray experiments were performed on CAL-1 cells after stimulation either with CL264, 9.2s RNA, or the combination of both. An early time point for this analysis (4 hrs) was chosen to minimize secondary effects, such as autocrine/paracrine
Figure 1: Cytokine and interferon secretion from CAL-1 cells upon stimulation with CL264 and 9.2s RNA. CAL-1 cells were seeded into 96-well plates. After overnight resting, cells were stimulated with CL264 or 9.2s RNA (complexed with PLarg) or the combination of both. After incubation as indicated, cell supernatant was analyzed for TNF-α, IL-6, and IFN-β by ELISA. (a) Secretion of TNF-α upon stimulation with CL264 in concentrations from 0.5 to 10 μg/mL and with 9.2s RNA in concentrations from 1 to 2 μg/mL for 6 hrs. (b) (c) (d) Secretion of TNF-α (b), IL-6 (c), and IFN-β (d) upon stimulation with CL264 (5 μg/mL), with 9.2s RNA (2 μg/mL) or the combination of both for 1, 4, and 12 hrs. (e) Secretion of TNF-α upon sequential stimulation. First, cells were incubated with CL264 (5 μg/mL; left hatched bar) or 9.2s RNA (2 μg/mL; right hatched bar) for 2 hrs, followed by 3 wash steps. After subsequent stimulation with the other ligand for additional 6 hrs, cytokine secretion into the supernatant was measured. (f) Secretion of TNF-α upon stimulation with CL264 (5 μg/mL), with 9.2s RNA (2 μg/mL) or with a combination of CL264 and PLarg (2 mg/mL), noncomplexed 9.2s RNA, or nonstimulatory Poly-A RNA (2 μg/mL) for 6 hrs. **P < 0.005.

cytokine stimulation. All treatment groups were normalized to untreated controls. Beside the characterization of genes significantly upregulated by either treatment, main goal was the identification of underlying regulatory genes that play a central role for synergistic effects.

Using a statistical cutoff of p < 0.001, treatment with 9.2s RNA significantly increased expression of 17 genes in CAL-1 cells, while treatment with CL264 resulted in an upregulation of 111 genes (Figure 2(a)). However, costimulation with both TLR7 ligands resulted in a synergistic upregulation of 388 genes, thereby upregulating significantly more genes than the sum of genes upregulated by either ligand alone. Interestingly, the majority of the upregulated genes in the monostimulatory groups (n = 112, 92%) were also present in the costimulatory
group. Furthermore, we addressed the question whether the unique genes significantly upregulated solely by costimulation \((n = 276, 71\%)\) were also increased in the monostimulatory groups when the statistical cutoff was lowered by one magnitude \((p < 0.01)\). In this case, 96 additional genes could be ascribed to either of the monostimulatory groups. Altogether, 208 genes \((54\% \text{ of } 388 \text{ genes}; p < 0.01)\) in the costimulatory group were significantly upregulated in either of the monostimulatory groups. Overall, these results indicate that the synergistic effect found in the costimulatory group is partially due to a stronger stimulation of already regulated genes but furthermore an effect of the upregulation of so far unregulated genes.

We next addressed the question whether costimulation with CL264 and 9.2s RNA also resulted in a significant increase of gene activation in terms of magnitude. Therefore, we analyzed the expression levels of the 50 most significantly upregulated genes in each treatment group. Results show that the average fold change increased from 1.11 \((9.2s \text{ RNA})\) and 7.17 \((\text{CL264})\) to 19.6 \((9.2s \text{ RNA/CL264})\) (Figure 2(b)) compared to untreated cells. Together, these results indicate that costimulation with 9.2s RNA and CL264 resulted in a synergistic effect on gene expression in terms of both number and magnitude of upregulated genes compared to monostimulation.

3.3. Analysis of Pathways, Functional Groups, and Regulatory Networks Triggered by 9.2s RNA Plus CL264. IPA was used to identify significantly regulated canonical pathways and functional groups. IPA characterizes gene products based on their function and role in regulatory pathways. Top scoring canonical pathways were “activation of IRF by cytosolic pattern recognition receptors” \((p < 4.31E−13)\), “dendritic cell maturation” \((p < 1.08E−10)\), and “interferon signaling” \((p < 5.94E−10)\). Top scoring functional groups were, for example, “cellular development, growth, and proliferation” \((p < 7.26E−34)\), “cell death and survival” \((p < 5.72E−29)\), “infectious disease” \((p < 1.6E−24)\), and “inflammatory response” \((p < 1.2E−20)\) (for more see Tables 1 and 2). These results indicate that the synergistic effect especially refers to immune-related processes.

Furthermore, IPA was used to identify the pattern of regulatory interactions underlying synergistic gene activation after costimulation with 9.2s RNA and CL264. The network analysis enabled us to define the regulatory nodes of this synergistic regulation. Major regulators were previously defined as regulatory nodes that trigger more than 30% of the costimulatory network, while minor regulators were defined as regulating 10% to <30% of the network \([13, 14]\). Applying this analysis revealed IL-1β, IL-6, and IFN-β as major regulatory nodes, while several minor regulatory nodes were also identified \((\text{NF-κB-1, REL, STAT1, CSF2, IRF1, and JUN})\) (Figure 3). Together, the major regulators \((\text{IL-1β, IL-6, TNF, and IFN-β})\) impacted the expression of around 95% of all genes within the network of the costimulatory group, while the minor regulators only had modulatory properties on the induced gene expression network.
3.4. Identification of Genes Synergistically Upregulated by 9.2s RNA Plus CL264. Evidence that the combination of CL264 and 9.2s RNA synergistically enhanced the secretion of certain cytokines and induced broader networks of gene regulation led us to examine which specific genes were synergistically upregulated by the combination of 9.2s RNA and CL264. Therefore, genes in the costimulated group with expressions being upregulated 1.5-fold of the sum induced by the ligands 9.2s RNA and CL264 alone were defined as being synergistically regulated. 62 genes were identified to be synergistically regulated by this criterion (Table 3). Out of these genes, 65% were functionally related to “immune response” regulation and 60% were related to “cellular growth and proliferation.” Furthermore, three out of four major
3.5. Coincubation with 9.2s RNA Enhances Binding of CL264 to CAL-1 Cells. To gain a more functional insight into the synergistic effect of CL294 and 9.2s RNA, we finally performed surface binding studies, since microarray analysis suggested that CL264 had a stronger impact on CAL-1 cells when being coadministered with 9.2s RNA. Therefore, CAL-1 cells were incubated with FITC-labeled CL264 alone or in combination with 9.2s RNA. The binding to the cell surface was determined by FACS analysis (Figure 4(a)). Cells being incubated with 9.2s RNA and FITC as control showed no increase in fluorescence signaling compared to the incubation with FITC alone. However, the combination of 9.2s RNA significantly enhanced the binding of FITC-labeled CL264 to the surface of the cells after a 10-minute stimulation period compared to the FITC control (221%, \( p < 0.001 \), Figure 4(b)). RNA not being complexed to PLarg or PLarg alone used as controls had no enhancing effect on the binding of labeled CL264.

4. Conclusions

TLRs are essential for host immunity by recognizing conserved structures in pathogens which trigger innate immune responses and prime antigen-specific adaptive immunity [1]. Among the nucleic acid-sensing TLRs 3, 7, and 9, all being located intracellularly, TLR7 and TLR9 share many common characteristics [15–17]. TLR7 and TLR9 ligands have shown promise in clinical trials as immunotherapeutics for the treatment of cancer, allergy, and infectious diseases [6, 18, 19]. By utilizing the human pDC line CAL-1, we were able to demonstrate a so far undescribed synergistic immune activation by the simultaneous use of CL264 and 9.2s RNA. In particular, costimulation with both ligands resulted in a supra-additive induction of proinflammatory cytokines (IL-6 and TNF-\( \alpha \)) as well as type 1 IFN (Figure 1). Microarray analysis showed that simultaneous use of both ligands synergistically activated genes primarily associated with immune processes (Figure 3). Mechanistically, surface binding studies revealed the enhanced uptake of CL264 in the presence of 9.2s RNA (Figure 4), which could account for the observed synergism.

PDCs were chosen for this study because they respond to TLR7 and are key players linking the innate and adaptive immune response. Of note, the use of human primary pDCs is inherently difficult for two reasons; first, pDCs are present in very low frequency in human peripheral blood and lymphoid tissue, accounting for approximately 0.2–0.5% of PBMC [20]; second, any efforts in purifying pDCs are likely to activate (prime) the cells, which contorts pattern of subsequent stimulation. As an alternative, the human pDC-derived CAL-1 line was studied. This cell line shares many of the phenotypic and functional properties of freshly isolated human pDCs and mirrors their response to TLR stimulation [9, 11, 21].

We stimulated our cells simultaneously with two different ligands for TLR7. Similarly to the substituted 8-hydroxyadenine derivative SM360320, CL264 induces the activation of NF-\( \kappa \)B and the secretion of type 1 IFN in TLR7-expressing cells [22]. CL264 ligand activity is TLR7-specific, it does not stimulate TLR8 even at high concentrations (>10 \( \mu \)g/mL). The immunostimulatory properties of the single-stranded RNA 9.2s were first described in 2005, when Hornung et al. originally intended to design different siRNAs (named 9.1 to 9.4) downregulating the human TLR9 to avoid effects of non-target-related IFN induction in human PDCs [8]. In fact, transfection of HEK293 cells with these RNAs reduced TLR9 expression. However, when the authors of that study transfected human pDCs using these siRNAs, they surprisingly noted a consistent pattern of type 1 IFN production, with siRNA 9.2 being the strongest inducer of IFN production. Additional analyses revealed that a specific
Table 3: Genes synergistically upregulated by the combination of 9.2s RNA and CL264.

| Gene name                              | Unigene ID | Gene symbol | 9.2s RNA | CL264 | 9.2s RNA + CL264 | Synergistic increase |
|----------------------------------------|------------|-------------|----------|-------|------------------|---------------------|
| CD69 molecule                          | Hs.208854  | CD69        | 2.4      | 6.1   | 64.2             | 7.6                 |
| BCL2-related protein A1                | Hs.227817  | BCL2A1      | 2.7      | 22.2  | 96.6             | 3.9                 |
| baculoviral IAP repeat containing 3   | Hs.127799  | BIRC3       | 1.2      | 6.4   | 25.6             | 3.4                 |
| RALBP1 associated Eps domain containing 2 | Hs.186810  | REPS2       | 1.0      | 2.4   | 10.3             | 3.1                 |
| Interferon, beta 1, fibroblast         | Hs.93177   | IFNBI       | 1.6      | 1.9   | 10.8             | 3.1                 |
| Suppressor of tumorigenicity 20        | Hs.729127  | ST20        | 1.3      | 4.8   | 18.5             | 3.0                 |
| Chemokine (C-C motif) ligand 2         | Hs.303649  | CCL2        | 0.6      | 41.4  | 126.0            | 3.0                 |
| CD44 molecule                          | Hs.502328  | CD44        | 1.5      | 4.3   | 17.5             | 3.0                 |
| Early growth response 3                | Hs.534313  | EGR3        | 2.1      | 3.3   | 15.9             | 2.9                 |
| Tubulin tyrosine-like family           | Hs.520554  | TTLL2       | 1.1      | 3.1   | 11.9             | 2.8                 |
| Oligomucleotide/oligosaccharide-binding fold containing 2A | Hs.591600  | OBF2CA      | 1.7      | 12.4  | 38.6             | 2.7                 |
| Interleukin 6 (interferon, beta 2)     | Hs.654458  | IL-6        | 0.9      | 4.9   | 14.7             | 2.6                 |
| Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha | Hs.81328   | NFKBIA      | 1.6      | 6.2   | 19.6             | 2.5                 |
| MIR155 host gene (non-protein-coding) (MIR155HG), noncoding RNA. | N/A    | MIR155HG   | 1.5      | 1.9   | 8.1             | 2.4                 |
| Chemokine (C-C motif) ligand 1         | Hs.72918   | CCL1        | 2.4      | 15.6  | 41.8             | 2.3                 |
| RasGEF domain family, member 1B       | Hs.591696  | RASGEF1B    | 1.1      | 3.3   | 10.2             | 2.3                 |
| CD70 molecule                          | Hs.501497  | CD70        | 1.4      | 6.1   | 16.5             | 2.2                 |
| G protein-coupled receptor 183         | Hs.784     | GPR183      | 1.0      | 2.6   | 7.8             | 2.2                 |
| ADAM metalloproteinase with thrombospondin type 1 motif, 10 | Hs.657508  | ADAMTS10    | 1.0      | 1.9   | 6.1             | 2.1                 |
| ADAM metalloproteinase domain 19       | Hs.483944  | ADAM19      | 2.4      | 3.6   | 12.6             | 2.1                 |
| FSHD region gene 2 family, member C   | Hs.274541  | FRG2C       | 0.8      | 1.1   | 4.1             | 2.1                 |
| Interleukin 23, alpha subunit p19     | Hs.98309   | IL-23A      | 1.6      | 7.8   | 19.4             | 2.1                 |
| EF-hand calcium binding domain 3      | Hs.152670  | EFCA3       | 1.0      | 1.3   | 4.8             | 2.1                 |
| Neutrophil cytosolic factor 2         | Hs.587558  | NCF2        | 1.8      | 3.8   | 11.5             | 2.1                 |
| Interleukin 1, beta                   | Hs.126256  | IL-1B       | 1.0      | 7.3   | 17.0             | 2.1                 |
| Nuclear receptor subfamily 4, group A, member 3 | Hs.279522 | NRA4A3      | 1.4      | 3.1   | 9.4             | 2.1                 |
| Tumor necrosis factor, alpha-induced protein 3 | Hs.211600 | TNFAIP3     | 1.5      | 3.5   | 10.2             | 2.1                 |
| Regulator of G-protein signaling 1    | Hs.75256   | RGS1        | 1.7      | 3.5   | 10.7             | 2.0                 |
| Serum/glucocorticoid regulated kinase 1 | Hs.510078  | SGK1        | 0.5      | 1.8   | 4.8             | 2.0                 |
| v-rel reticuloendotheliosis viral oncogene homolog | Hs.631886 | REL       | 1.1      | 2.4   | 6.7             | 2.0                 |
| Immediate early response 3            | Hs.76095   | IER3        | 0.8      | 4.3   | 9.9             | 1.9                 |
| Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta | Hs.319171 | NFKBIZ      | 1.3      | 2.7   | 7.8             | 1.9                 |
| Chemokine (C-C motif) ligand 4-like 2 | Hs.661942  | CCL4L2      | 2.0      | 21.0  | 43.9             | 1.9                 |
| Interleukin 18 receptor 1             | Hs.469521  | IL-18R1     | 2.5      | 6.9   | 17.9             | 1.9                 |
| Interleukin 8 (IL8)                   | Hs.624     | IL-8        | 1.8      | 2.4   | 7.9             | 1.9                 |
| CASP8 and FADD-like apoptosis regulator | Hs.390736  | CFLAR       | 1.5      | 2.2   | 6.8             | 1.9                 |
| pim-2 oncogene                         | Hs.496096  | PIM2        | 0.8      | 3.0   | 7.1             | 1.8                 |
| Spermidine/spermine N1-acetyltransferase 1 | Hs.28491  | SAT1        | 1.6      | 3.6   | 9.5             | 1.8                 |
| Interleukin 4 induced 1               | Hs.574492  | IL-4I       | 1.2      | 4.0   | 9.4             | 1.8                 |
| Chemokine (C-X-C motif) ligand 10     | Hs.632586  | CXCL10      | 1.6      | 5.8   | 13.1             | 1.8                 |
| Solute carrier family 29 (nucleoside transporters), member 2 | Hs.569017  | SLC29A2     | 1.4      | 3.4   | 8.6             | 1.8                 |
Table 3: Continued.

| Gene name | Unigene ID | Gene symbol | Transcript level (fold over nonstimulated control) | 9.2s RNA | CL264 | 9.2s RNA + CL264 | Synergistic increase |
|-----------|------------|-------------|----------------------------------------------------|---------|-------|-----------------|---------------------|
| Long intergenic non-protein-coding RNA 173, noncoding RNA. | N/A | LINC00173 | 1.8 | 3.2 | 8.8 | 1.8 |
| Mitogen-activated protein kinase kinase kinase 8 | Hs.432453 | MAP3K8 | 1.1 | 4.1 | 9.1 | 1.8 |
| Signal transducer and activator of transcription 5A | Hs.437058 | STAT5A | 0.8 | 1.9 | 4.6 | 1.7 |
| ADP-ribosylation factor-like 5B | Hs.25362 | ARL5B | 1.5 | 3.1 | 7.9 | 1.7 |
| Ninjurin 1 | Hs.494457 | NINJ1 | 0.9 | 3.4 | 7.3 | 1.7 |
| Wingless-type MMTV integration site family, member 10A | Hs.121540 | WNT10A | 1.2 | 5.8 | 11.6 | 1.6 |
| B cell translocation gene 1, antiproliferative | Hs.255935 | BTG1 | 1.5 | 2.6 | 6.7 | 1.6 |
| Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) | Hs.118400 | FSCN1 | 0.5 | 1.6 | 3.5 | 1.6 |
| CD83 molecule | Hs.595133 | CD83 | 1.7 | 5.2 | 11.4 | 1.6 |
| Platelet-derived growth factor alpha polypeptide | Hs.535898 | PDGFA | 1.4 | 2.3 | 6.1 | 1.6 |
| Transcription factor E | Hs.125962 | TFEC | 0.6 | 3.1 | 6.1 | 1.6 |
| CD40 molecule, TNF receptor superfamily member 5 | Hs.472860 | CD40 | 1.0 | 4.1 | 8.4 | 1.6 |
| POU class 2 homeobox 2 | Hs.654420 | POU2F2 | 0.6 | 3.2 | 6.2 | 1.6 |
| Nuclear receptor coactivator 7 | Hs.171426 | NCOA7 | 1.6 | 2.7 | 6.8 | 1.6 |
| Zinc finger protein 36, C3H type-like 1 | Hs.85155 | ZFP36L1 | 1.3 | 2.0 | 5.1 | 1.6 |
| Solute carrier family 7, member II | Hs.390594 | SLC7A11 | 1.4 | 2.2 | 5.7 | 1.6 |
| FSHD region gene 2 | Hs.626907 | FRG2 | 1.1 | 1.3 | 3.7 | 1.5 |
| Homo sapiens microRNA miR-146 stem-loop | N/A | hsa-mir-146a | 1.1 | 3.7 | 7.3 | 1.5 |
| Homo sapiens microRNA miR-21 stem-loop | N/A | hsa-mir-21 | 1.6 | 1.7 | 5.1 | 1.5 |
| BTB (POZ) domain containing 19 | Hs.632400 | BTBD19 | 0.8 | 1.7 | 3.9 | 1.5 |
| ELOVL fatty acid elongase 6 | Hs.412939 | ELOVL6 | 1.1 | 1.7 | 4.2 | 1.5 |

CAL-1 cells were treated as described above (see Table 1). The table lists specific genes synergistically upregulated by the combination of 9.2s RNA and CL264. Genes in the costimulated group with expressions being upregulated 1.5-fold of the sum induced by the ligands 9.2s RNA and CL264 alone were defined as being synergistically regulated.

Microarrays facilitate the evaluation of global changes in gene expression induced by immune stimuli [23–25]. This has led others to use microarray approaches to monitor global changes of gene expression induced by the combination of several inflammatory stimuli [26–29]. In general, almost all studies observed synergistic upregulation of immune-related genes when combining ligands for different TLRs [27, 29]. Rationale is always the simultaneous activation of different pathways inducing a supra-additive immune activation. However, we opted for a slightly different approach by creating synergistic effects using structurally different ligands targeting the same receptor. We observed a more than 3-fold increase in the number of genes upregulated by the combination of CL264 and 9.2s RNA compared to CL264 alone (Figure 2(a)). Additionally, the overall magnitude of gene upregulation was increased by more than 2.5-fold when comparing the top 50 genes induced upon combination of both ligands versus CL264 alone (Figure 2(b)). Studies of protein production by ELISA confirmed the synergistic activation of regulatory members such as IL-6, TNF, and IFN-β (Figure 1). These findings suggest that simultaneous exposure to both ligands magnified and accelerated the response elicited by each individual ligand. Importantly, the vast majority of genes upregulated by stimulating with either ligand alone were also induced in the costimulatory setting (92%). Investigating the genes upregulated in the combined CL264/9.2s RNA group, nearly 54% of them were also upregulated in the monostimulatory settings (although at a lower p value). Taken together, this indicates a stronger stimulation of genes yet upregulated upon stimulation by either ligand. On the other hand, this finding also delineates the upregulation of new or rather so far unregulated genes by the combination of CL264/9.2s RNA (46% of the genes). These synergistic effects primarily broaden the existing immune response, rather than creating a new one. This observation is supported by the fact that the functional groups (analyzed by IPA) induced by the combinatory versus single stimulation did not alter qualitatively (innate immune function such as IRF signaling or DC maturation (Table 2)).

Finally, exclusive IPA analysis of the 62 synergistically upregulated genes (defined as upregulated 1.5-fold of the sum induced by the ligands 9.2s RNA and CL264 alone;
see Table 3) revealed that 65% were immune-related. Indeed, more than 35% of all synergistically upregulated genes, including the most highly upregulated, coded for cytokines, chemokines, or transcription regulators (such as IL-1b, IL-6, IL-18R, IL-23A, CCL1, CCL2, REL, and NFKBIZ). These findings support the hypothesis that stimulation via different TLR7 ligands synergistically broadens and increases the magnitude of the host’s protective immune response. A similar observation has recently been made by Du et al., who showed that the combination of small phosphothioate ODNs with the TLR7/8 agonist CL075 (a chemical base analog comparable to CL264) induced a synergistic response in murine glial cells with substantially higher levels of proinflammatory cytokines and chemokines compared to CL075 [30]. Mechanistically, that work suggested intracellular processes underlying these synergistic effects. However, we identified another possible cause. Using a FACS-based binding assay, we showed increased cell surface binding (>2-fold) of CL264...
upon combination with 9.2s RNA compared to CL264 alone (Figure 4). By stimulating the cells sequentially, 9.2s RNA could be identified as being accountable for this phenomenon (Figure 1(f)). Although the mechanistic background remains to be elucidated, this finding suggests an optimized surface binding and subsequent cellular uptake into the endosomal compartment as one explanation for the observed synergistic effects of CL264 and 9.2s RNA. Of note, this effect is not due to the use of the cationic polypeptide Plarg together with 9.2s RNA, since synergy was not observed when CL264 was administered with Plarg alone. Further investigations are necessary to clarify whether binding is limited at the cell surface or leads to enhanced localization of CL264 within the endosomes in the presence of 9.2s RNA, maybe using confocal microscopy.

We cannot rule out further additive effects on the receptor level using both types of ligands. With regard to the above-mentioned properties of 9.2s RNA, our microarray data do not show any evidence for a specific influence of 9.2s RNA on the closely related TLR9 pathway (data not shown). Since CAL-1 cells do not express the TLR8, costimulatory effects of TLR7 and TLR8 by the use of ssRNA and CL264 are highly improbabler. However, Tanji et al. very recently showed two distinct binding sites of ssRNA fragments and chemical ligands at TLR8 leading to synergistic effects when being simultaneously activated. Since TLR7 and TLR8 are closely related and recognize the same ligands, it is conceivable that the same phenomenon also accounts for TLR7. Thus, optimal stimulation of TLR7 at different binding sites by ssRNA and base analogs could also contribute to the observed synergistic effects of this study. Upcoming experiments are designed to gain more mechanistic insights into the intracellular level underlying these effects by combining different ssRNA motifs and CL264.

Although various synthetic TLR7/8 agonists have been used as adjuvants during preclinical trials, not many of them are approved for use in humans. The TLR7/8 agonist R837 is used for the topical treatment of genital warts, basal cell carcinoma, and bladder cancer. However, systemic application of imidazoquinolines causes adverse side effects, and the development of other TLR7 agonists suitable for nontopical use as adjuvants is desirable.

Our study has some limitations. Despite the fact that CAL-1 cells share many of the phenotypic and functional properties of human pDCs, Maeda et al. have described some significant differences between this cell line and freshly isolated primary human pDCs including little IFN-α secretion in response to TLR stimulation. It is well accepted that working with purified human pDCs is challenging, since they are extremely sensible to any kind of physical manipulation (such as purifying them using different sorting techniques), resulting in significant cytokine release acting in a paracrine and autocrine fashion. Kim et al. recently demonstrated that low levels of background IFN-β (so-called primed pDCs) resulted in a strong feedforward regulation of their TLR-triggered type 1 IFN production in vitro and concluded that the in vitro activity of a TLR ligand on primary pDCs does not necessarily correspond to its in vivo activity. However, we and many other groups have meanwhile shown that CAL-1 cells are suitable surrogates to study specific aspects of human pDC physiology and TLR7 and TLR9. For the herein presented study, we chose to focus on IFN-β (instead of IFN-α) since we studied early time point effects up to 12 hours to minimize the mentioned auto- and paracrine cytokine effects, which is essential when studying synergism of different TLR ligands. We previously demonstrated that, in contrast to IFN-β, IFN-α expression peaks rather late (>24 hours) in response to TLR stimulation, which is likewise influenced by a type I IFN feedback loop.

A number of studies analyzed synergistic effects activating different TLRs. However, to our knowledge, the present study is the first to provide fundamental new insights into the simultaneous activation of a single toll-like receptor. Using the human pDC-like cell line CAL-1, we demonstrated that structurally different TLR7 ligands act synergistically on gene expression patterns of the inflammatory response. This phenomenon may be explained in part by an enhanced binding of CL264 in the presence of 9.2s RNA. However, future studies will need to further elucidate intracellular mechanisms, as suggested by recent studies. Taken together, our data could impact future strategies optimizing TLR7-targeted drug design and provide new insights into the synergistic interactions of structurally different TLR7 ligands.

**Conflict of Interests**

The authors state that there exists no conflict of interests.

**Authors’ Contribution**

Tobias Hilbert and Folkert Steinhagen contributed equally to this work.

**Acknowledgments**

The authors would like to thank Dr. T. Maeda and Dr. S. Kamihira (Department of Island Medicine, Nagasaki University, Japan) for providing CAL-1 cells. The authors further thank Stillia Frede and Mario Fox for providing technical support and Catherine Widmann for language editing. Analyses were performed using BRB-ArrayTools developed by Dr. Richard Simon and BRB-ArrayTools Development Team.

**References**

[1] T. Kawai and S. Akira, “The role of pattern-recognition receptors in innate immunity: update on toll-like receptors,” Nature Immunology, vol. 11, no. 5, pp. 373–384, 2010.

[2] P. Fitzgerald-Bocarsly, J. Dai, and S. Singh, “Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history,” Cytokine and Growth Factor Reviews, vol. 19, no. 1, pp. 3–19, 2008.

[3] D. Jarrossay, G. Napolitani, M. Colonna, F. Sallusto, and A. Lanzavecchia, “Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid

dendritic cells," European Journal of Immunology, vol. 31, no. 11, pp. 3388–3393, 2001.

[4] N. Kadowaki, S. Ho, S. Antonenko et al., “Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens," Journal of Experimental Medicine, vol. 194, no. 6, pp. 863–869, 2001.

[5] N. Simchoni and C. Cunningham-Rundles, "TLR7- and TLR9-responsive human B cells share phenotypic and genetic characteristics," The Journal of Immunology, vol. 194, no. 7, pp. 3035–3044, 2015.

[6] F. Steinhagen, T. Kinjo, C. Bode, and D. M. Klinman, “TLR-based immune adjuvants," Vaccine, vol. 29, no. 17, pp. 3341–3355, 2011.

[7] V. Gosu, S. Basith, O.-P. Kwon, and S. Choi, "Therapeutic applications of nucleic acids and their analogues in toll-like receptor signaling," Molecules, vol. 17, no. 11, pp. 13503–13529, 2012.

[8] V. Hornung, M. Guenthner-Biller, C. Bourquin et al., "Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7," Nature Medicine, vol. 11, no. 3, pp. 263–270, 2005.

[9] F. Steinhagen, A. P. McFarland, L. G. Rodriguez et al., "IRF-5 and NF-kB p50 co-regulate IFN-β and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells," European Journal of Immunology, vol. 43, no. 7, pp. 1896–1906, 2013.

[10] Y. H. Yang, S. Dudoit, P. Luu et al., "Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation," Nucleic Acids Research, vol. 30, article e15, 2002.

[11] T. Maeda, K. Murata, T. Fukushima et al., "A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma," International Journal of Hematology, vol. 81, no. 2, pp. 148–154, 2005.

[12] F. Steinhagen, C. Meyer, D. Tross et al., "Activation of type I interferon-dependent genes characterizes the 'core response' induced by CpG DNA," Journal of Leukocyte Biology, vol. 92, no. 4, pp. 775–785, 2012.

[13] S. Klaschik, D. Tross, and D. M. Klinman, "Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo," Journal of Leukocyte Biology, vol. 85, no. 5, pp. 788–795, 2009.

[14] S. Klaschik, D. Tross, H. Shirota, and D. M. Klinman, "Short- and long-term changes in gene expression mediated by the activation of TLR9," Molecular Immunology, vol. 47, no. 6, pp. 1317–1324, 2010.

[15] M. Sasai, M. M. Linehan, and A. Iwasaki, "Bifurcation of toll-like receptor 9 signaling by adaptor protein 3," Science, vol. 329, no. 5998, pp. 1530–1534, 2010.

[16] C. Guiducci, G. Ott, J. H. Chan et al., "Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation," Journal of Experimental Medicine, vol. 203, no. 8, pp. 1999–2008, 2006.

[17] K. Honda, Y. Ohba, H. Yanai et al., "Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction," Nature, vol. 434, no. 7036, pp. 1035–1040, 2005.

[18] Z. Aryan, S. T. Holgate, D. Radzioch, and N. Rezaei, "A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma," International Archives of Allergy and Immunology, vol. 164, no. 1, pp. 46–63, 2014.

[19] L. A. J. O’Neill, C. E. Bryant, and S. L. Doyle, “Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer," Pharmacological Reviews, vol. 61, no. 2, pp. 177–197, 2009.

[20] F. P. Siegal, N. Kadowaki, M. Shodell et al., “The nature of the principal type 1 interferon-producing cells in human blood," Science, vol. 284, no. 5421, pp. 1835–1837, 1999.

[21] B. Cisse, M. L. Caton, M. Lehner et al., "Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development," Cell, vol. 135, no. 1, pp. 37–48, 2008.

[22] S. Dharmapuri, L. Aurisicchio, P. Neuner, M. Verdirame, G. Ciliberto, and N. La Monica, "An oral TLR7 agonist is a potent inducer of DNA vaccination in transgenic mouse tumor models," Cancer Gene Therapy, vol. 16, no. 5, pp. 462–472, 2009.

[23] S. Klaschik, I. Gursel, and D. M. Klinman, "CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis," Molecular Immunology, vol. 44, no. 6, pp. 1095–1104, 2007.

[24] C. C. Huang, K. E. Duffy, L. R. San Mateo, B. Y. Amegadzie, R. T. Sarisky, and M. L. Mbow, “A pathway analysis of poly(I:C)-induced global gene expression change in human peripheral blood mononuclear cells," Physiological Genomics, vol. 26, no. 2, pp. 125–133, 2006.

[25] M. Duggan, D. You, J. O. Cleaver et al., “Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice," The Journal of Immunology, vol. 186, no. 10, pp. 5916–5926, 2011.

[26] D. Tross, L. Petrenko, S. Klaschik, Q. Zhu, and D. M. Klinman, "Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3," Molecular Immunology, vol. 46, no. 13, pp. 2557–2564, 2009.

[27] Q. Zhu, C. Engelston, A. Vivekanandhan et al., "Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 42, pp. 16260–16265, 2008.

[28] G. Napolitani, A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia, "Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells," Nature Immunology, vol. 6, no. 8, pp. 769–776, 2005.

[29] M. Du, N. B. Butchi, T. Woods, and K. E. Peterson, "Polythymidine oligonucleotides mediate activation of murine glial cells primarily through TLR7, not TLR8," PLoS ONE, vol. 6, no. 7, Article ID e22454, 2011.

[30] H. Tanji, U. Ohto, T. Shibata et al., "Toll-like receptor 8 senses degradation products of single-stranded RNA," Nature Structural and Molecular Biology, vol. 22, pp. 109–115, 2015.

[31] D. Rajagopal, C. Paturel, Y. Morel, S. Uematsu, S. Akira, and S. S. Diebold, "Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists," Blood, vol. 115, no. 10, pp. 1949–1957, 2010.

[32] P. Savage, V. Horton, J. Moore, M. Owens, P. Witt, and M. E. Gore, "A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily," British Journal of Cancer, vol. 74, no. 9, pp. 1482–1486, 1996.

[33] S. Gallucci, M. Lolkema, and P. Matzinger, "Natural adjuvants: endogenous activators of dendritic cells," Nature Medicine, vol. 5, no. 11, pp. 1249–1255, 1999.
[35] S. Kim, V. Kaiser, E. Beier et al., “Self-priming determines high type I IFN production by plasmacytoid dendritic cells,” European Journal of Immunology, vol. 44, no. 3, pp. 807–818, 2014.

[36] J. J. Karrich, M. Balzarolo, H. Schmidlin et al., “The transcription factor Spi-B regulates human plasmacytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1,” Blood, vol. 119, no. 22, pp. 5191–5200, 2012.

[37] J. J. Karrich, L. C. M. Jachimowski, M. Libouban et al., “MicroRNA-146a regulates survival and maturation of human plasmacytoid dendritic cells,” Blood, vol. 122, no. 17, pp. 3001–3009, 2013.

[38] X. Zhang, W. Sun, X. Wu et al., “An oligodeoxynucleotide with CCT repeats restraints CpG ODN-induced TLR9 trafficking,” Current Pharmaceutical Biotechnology, vol. 15, no. 9, pp. 780–789, 2014.